
Chiara Bianca Maria Platania

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6525673/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The P2X7 receptor as a new pharmacological target for retinal diseases. Biochemical Pharmacology, 2022, 198, 114942.	2.0	12
2	Circulating miRNAs in diabetic retinopathy patients: Prognostic markers or pharmacological targets?. Biochemical Pharmacology, 2021, 186, 114473.	2.0	19
3	Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye. International Journal of Molecular Sciences, 2021, 22, 4404.	1.8	12
4	Glucose-Impaired Corneal Re-Epithelialization Is Promoted by a Novel Derivate of Dimethyl Fumarate. Antioxidants, 2021, 10, 831.	2.2	6
5	1α,25-dihydroxyvitamin D3 protects retinal ganglion cells in glaucomatous mice. Journal of Neuroinflammation, 2021, 18, 206.	3.1	17
6	Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study. Frontiers in Pharmacology, 2021, 12, 718902.	1.6	13
7	Molecular Dynamics Simulation Techniques as Tools in Drug Discovery and Pharmacology: A Focus on Allosteric Drugs. Methods in Molecular Biology, 2021, 2253, 245-254.	0.4	13
8	Editorial: Chronic Inflammation and Neurodegeneration in Retinal Disease. Frontiers in Pharmacology, 2021, 12, 784770.	1.6	1
9	Targeting the miRNA-155/TNFSF10 network restrains inflammatory response in the retina in a mouse model of Alzheimer's disease. Cell Death and Disease, 2021, 12, 905.	2.7	16
10	Effects of Vitamin D3 and Meso-Zeaxanthin on Human Retinal Pigmented Epithelial Cells in Three Integrated in vitro Paradigms of Age-Related Macular Degeneration. Frontiers in Pharmacology, 2021, 12, 778165.	1.6	7
11	Do Extracellular RNAs Provide Insight into Uveal Melanoma Biology?. Cancers, 2021, 13, 5919.	1.7	6
12	Caffeine Protects Against Retinal Inflammation. Frontiers in Pharmacology, 2021, 12, 824885.	1.6	10
13	Stabilization of HIF-1Î \pm in Human Retinal Endothelial Cells Modulates Expression of miRNAs and Proangiogenic Growth Factors. Frontiers in Pharmacology, 2020, 11, 1063.	1.6	32
14	TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy. International Journal of Molecular Sciences, 2020, 21, 9558.	1.8	35
15	Novel Heme Oxygenase-1 (HO-1) Inducers Based on Dimethyl Fumarate Structure. International Journal of Molecular Sciences, 2020, 21, 9541.	1.8	9
16	Dihydrotanshinone, a Natural Diterpenoid, Preserves Blood-Retinal Barrier Integrity via P2X7 Receptor. International Journal of Molecular Sciences, 2020, 21, 9305.	1.8	17
17	New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery. Frontiers in Pharmacology, 2020, 11, 708.	1.6	8
18	Retinal biomarkers and pharmacological targets for Hermansky-Pudlak syndrome 7. Scientific Reports, 2020, 10, 3972.	1.6	7

#	Article	IF	CITATIONS
19	Resolvin D1 Modulates the Intracellular VEGF-Related miRNAs of Retinal Photoreceptors Challenged With High Glucose. Frontiers in Pharmacology, 2020, 11, 235.	1.6	33
20	Effects of protein-protein interface disruptors at the ligand of the glucocorticoid-induced tumor necrosis factor receptor-related gene (GITR). Biochemical Pharmacology, 2020, 178, 114110.	2.0	9
21	Novel indole derivatives targeting HuR-mRNA complex to counteract high glucose damage in retinal endothelial cells. Biochemical Pharmacology, 2020, 175, 113908.	2.0	27
22	Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochemical Pharmacology, 2020, 177, 114004.	2.0	36
23	Blood-retinal barrier protection against high glucose damage: The role of P2X7 receptor. Biochemical Pharmacology, 2019, 168, 249-258.	2.0	39
24	Aflibercept regulates retinal inflammation elicited by high glucose via the PIGF/ERK pathway. Biochemical Pharmacology, 2019, 168, 341-351.	2.0	57
25	Ocular Pharmacological Profile of Hydrocortisone in Dry Eye Disease. Frontiers in Pharmacology, 2019, 10, 1240.	1.6	27
26	Novel ophthalmic formulation of myriocin: implications in retinitis pigmentosa. Drug Delivery, 2019, 26, 237-243.	2.5	28
27	Retinal and circulating mi <scp>RNA</scp> expression patterns in diabetic retinopathy: An in silico and in vivo approach. British Journal of Pharmacology, 2019, 176, 2179-2194.	2.7	104
28	Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents. Future Medicinal Chemistry, 2019, 11, 1523-1536.	1.1	13
29	Therapeutic Potential of Nitric Oxide Modulation in Ocular Diseases: A Focus on Novel NO-Releasing Molecules. , 2019, , 333-334.		0
30	Antioxidant and Osmoprotecting Activity of Taurine in Dry Eye Models. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 188-194.	0.6	30
31	Computational systems biology approach to identify novel pharmacological targets for diabetic retinopathy. Biochemical Pharmacology, 2018, 158, 13-26.	2.0	43
32	Novel Therapeutics in Glaucoma Management. Current Neuropharmacology, 2018, 16, 978-992.	1.4	37
33	Topical Ocular Delivery of TGF-β1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases. International Journal of Molecular Sciences, 2017, 18, 2076.	1.8	34
34	Retinal and Circulating miRNAs in Age-Related Macular Degeneration: An In vivo Animal and Human Study. Frontiers in Pharmacology, 2017, 8, 168.	1.6	90
35	Effects of Novel Nitric Oxide-Releasing Molecules against Oxidative Stress on Retinal Pigmented Epithelial Cells. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-11.	1.9	37
36	P2X7 receptor antagonism: Implications in diabetic retinopathy. Biochemical Pharmacology, 2017, 138, 130-139.	2.0	71

#	Article	IF	CITATIONS
37	Current drug treatments targeting dopamine D3 receptor. , 2016, 165, 164-177.		87
38	TGF-β1 prevents rat retinal insult induced by amyloid-β (1–42) oligomers. European Journal of Pharmacology, 2016, 787, 72-77.	1.7	39
39	Characterization of Protein–Protein Interfaces through a Protein Contact Network Approach. Frontiers in Bioengineering and Biotechnology, 2015, 3, 170.	2.0	20
40	MicroRNA target prediction in glaucoma. Progress in Brain Research, 2015, 220, 217-240.	0.9	40
41	Nrf2 activators modulate oxidative stress responses and bioenergetic profiles of human retinal epithelial cells cultured in normal or high glucose conditions. Pharmacological Research, 2015, 99, 296-307.	3.1	65
42	Dopamine D3 receptor-dependent changes in alpha6 GABAA subunit expression in striatum modulate anxiety-like behaviour: Responsiveness and tolerance to diazepam. European Neuropsychopharmacology, 2015, 25, 1427-1436.	0.3	28
43	Controversies in Glaucoma: Current Medical Treatment and Drug Development. Current Pharmaceutical Design, 2015, 21, 4673-4681.	0.9	32
44	Dopamine D3 Receptor Is Necessary for Ethanol Consumption: An Approach with Buspirone. Neuropsychopharmacology, 2014, 39, 2017-2028.	2.8	52
45	Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. International Journal of Pharmaceutics, 2014, 470, 133-140.	2.6	72
46	Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammationâ€. Journal of Pharmacy and Pharmacology, 2014, 66, 954-960.	1.2	25
47	Dopamine D3 receptor as a new pharmacological target for the treatment of depression. European Journal of Pharmacology, 2013, 719, 25-33.	1.7	115
48	Regulation of intraocular pressure in mice: Structural analysis of dopaminergic and serotonergic systems in response to cabergoline. Biochemical Pharmacology, 2013, 86, 1347-1356.	2.0	16
49	Fortified Extract of Red Berry, <i>Ginkgo biloba</i> , and White Willow Bark in Experimental Early Diabetic Retinopathy. Journal of Diabetes Research, 2013, 2013, 1-6.	1.0	39
50	Homology Modeling of Dopamine D2 and D3 Receptors: Molecular Dynamics Refinement and Docking Evaluation. PLoS ONE, 2012, 7, e44316.	1.1	62